Substance / Medication

Histrelin

Overview

Active Ingredient
histrelin
RxNorm CUI
50975

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis David, Karavani Gilad, Hirsch Harry J et al. · J Pediatr · 2013
PMID: 23485026Observational
Prolonged Pubertal Suppression due to Retained Histrelin Implant in Three Children with Central Precocious Puberty.
Marpuri Ian, Geffner Mitchell E, Chao Lily C · Horm Res Paediatr · 2025
PMID: 40015262Case Report
Gonadotropin Suppression for 7 Years After a Single Histrelin Implant for Precocious Puberty.
Villalta Douglas, Quintos Jose B · J Endocr Soc · 2022
PMID: 35047716Case ReportFull text (PMC)
Drug-induced liver injury caused by the histrelin (Vantus) subcutaneous implant.
Ricker Jonathan M, Foody William F, Shumway Nathan M et al. · South Med J · 2010
PMID: 19996852Case Report
Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty.
Ray Lauren A, Eckert George J, Eugster Erica A · J Pediatr Endocrinol Metab · 2023
PMID: 36625262Other
Fertility preservation in transfeminine adolescents using TESE at the time of Histrelin Acetate subcutaneous implant placement: A Case Series.
Barrera Ellis, Locks Rachel, Kremen Jessica et al. · J Pediatr Urol · 2023
PMID: 37770134Other
Extended Use of Histrelin Implant in Pediatric Patients.
Pine-Twaddell Elyse, Newfield Ron S, Marinkovic Maja · Transgend Health · 2023
PMID: 37342480OtherFull text (PMC)
Trends in Histrelin Implantation at a Pediatric Tertiary Care Center.
Mak Allison, Hwang Rosa, Nace Gary et al. · J Surg Res · 2023
PMID: 37352739Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Histrelin (substance)
SNOMED CT
109049002
UMLS CUI
C0121902
RxNorm CUI
50975

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.